News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celsis In Vitro Technologies (CEL.L) and Promega Biosciences, Inc. to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes


2/12/2009 10:36:18 AM

BALTIMORE, Feb. 9 /PRNewswire/ -- Celsis In Vitro Technologies (Celsis IVT), a division of Celsis International plc, a Chicago-based life science products and laboratory services company, and Wisconsin-based Promega Corp will take the trial and guesswork out of ADME-Tox testing in primary hepatocytes. Celsis IVT is pre-qualifying lots of its extensive cryopreserved hepatocytes for use with Promega's bioluminescent ADME-Tox assays, including the P450-Glo(TM) CYP Assay used to study cytochrome P450 gene induction and inhibition and the GSH-Glo(TM) Glutathione Assay for investigating mechanisms of hepatotoxicity.

"Researchers are looking for validated solutions that are predictive," said Dr. James Cali, lead scientist for ADME-Tox at Promega. "Providing pre-qualified cryoplateable hepatocytes that work the first time and every time with our luminescent reagents has always been a goal for Promega. By validating lots from their extensive inventory in advance, Celsis IVT will help our customers save additional time in their research," he explained. "Together, we are taking the guesswork out of hepatocyte analysis."

Determining whether a particular lot of hepatocytes will work for a given application is time-consuming and costly. Much of the effort involves trial and error. Even when a suitable lot of hepatocytes is identified, current LC/MS technologies for measuring gene expression, enzyme activity or metabolite formation are expensive or require lengthy incubations times that often involve working evening or weekend hours. This collaborative effort between Promega and Celsis IVT will enable customers to quickly and easily identify and select both products that have been validated to work together, saving customers valuable time and resources, increasing efficiency and leading to the faster development of safe drugs.

"Celsis IVT is pleased to be working closely with Promega to help deliver a complete, validated and predictive solution to customers in the area of ADME-Tox assays," said Philip Vorwald, vice president and general manager of Celsis IVT. "Promega's P450-Glo CYP and GSH-Glo ADME-Tox assays enable scientists to get results faster. Now with our pre-qualified cell lots, Promega customers can eliminate the guesswork involved in testing cell lots, save analysis time and money, and have the greatest confidence in their results."

The two companies are collaborating on scientific presentations and publications demonstrating effective applications of the validated tools for ADME-Tox studies.

About Celsis

Celsis International plc is a world leading provider of innovative life science products and laboratory services to the pharmaceutical, biopharmaceutical, and consumer products industries through its three business areas: rapid microbial detection systems, analytical laboratory services and ADME-Tox in vitro products and services. The company is listed on the London Stock Exchange (CEL.L). Each division of Celsis International plc has the capacity to deliver substantial time and cost savings to its customers in addition to ensuring product quality and safety for consumers. Celsis In Vitro Technologies helps companies reduce the time and cost of drug development by supplying in vitro testing products to the pharmaceutical and biotechnology industries for screening drug compounds early in the discovery process. More information is online at http://www.celsis.com.

About Promega

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company's 2,000 products enable scientists worldwide to advance their knowledge in ADME-Tox, cellular analysis, genomics, proteomics and molecular diagnostics. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in twelve countries and 54 global distributors. Annual sales exceed $220 million. For more information about Promega, visit http://www.promega.com.

CONTACT: Penny Patterson, Director, Corporate Affairs of Promega,
+1-608-274-4330, penny.patterson@promega.com; or Cindy Lieberman, VP,
Communications of Celsis In Vitro Technologies, +1-312-476-1200,
clieberman@celsis.com

Web site: http://www.celsis.com/
http://www.promega.com/


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES